Capecitabine as Second-Line Therapy in Treating Patients With Stage IV Pancreatic Cancer Who Have the Thymidylate Synthase Gene

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed pancreatic cancer
• * Stage IV disease
• Measurable disease (≥ 1 cm or \> 10 mm lesion(s) by spiral CT scan)
• Disease progression after ≥ 1 gemcitabine-based treatment regimen for advanced/metastatic disease
• Patient carries the double tandem repeat (S/S) variant of the thymidylate synthase gene enhancer region (TSER)
• No active CNS metastases (indicated by clinical symptoms, cerebral edema, steroid requirement, or progressive growth)
• PATIENT CHARACTERISTICS:
• ECOG performance status 0-2
• Absolute neutrophil count ≥ 1,500/mm\^3
• Platelet count ≥ 100,000/mm\^3
• AST/ALT ≤ 2.5 times upper limit of normal (ULN) (5 times ULN if attributable to liver metastases)
• Total bilirubin ≤ 1.5 times ULN
• Creatinine normal OR creatinine clearance \> 50 mL/min
• Fertile patients must use effective contraception during and for 30 days after completion of study treatment
• Not pregnant or nursing
• Negative pregnancy test
• Asymptomatic HIV infection allowed
• No recent or ongoing clinically significant gastrointestinal disorder (e.g., malabsorption, bleeding, inflammation, emesis, or diarrhea \> grade 1)
• Able to swallow capecitabine tablets
• No known hypersensitivity to fluorouracil
• No dihydropyrimidine dehydrogenase (DPD) deficiency
• No clinically significant cardiac disease (e.g., congestive heart failure, symptomatic coronary artery disease, or cardiac arrhythmias not well controlled with medication)
• No myocardial infarction within the past 6 months
• No serious, uncontrolled, concurrent infection(s)
• No prior unanticipated severe reaction to fluoropyrimidine therapy
• No other malignancy within the past 5 years except cured nonmelanoma skin cancer or treated carcinoma in situ of the cervix
• PRIOR CONCURRENT THERAPY:
• See Disease Characteristics
• At least 3 weeks since prior chemotherapy
• No prior capecitabine except in the adjuvant setting
• At least 3 weeks since prior radiotherapy or major surgery
• At least 4 weeks since prior participation in any investigational drug study
• At least 4 weeks since prior sorivudine or brivudine
• No concurrent sorivudine or brivudine
• No concurrent cimetidine or azidothymidine (AZT)
• Concurrent radiotherapy for bone pain allowed to a limited field provided ≥ 1 indicator lesion remains outside of the field
• No other concurrent chemotherapy or immunotherapy